Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well infigratinib works in treating solid tumors that have
spread to other places in the body (advanced or metastatic) in patients with FGFR gene
mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any
changes in the genetic material (DNA) of a cell. FGFR proteins are involved in cell division,
cell maturation, formation of new blood vessels, wound healing, and bone growth, development,
and maintenance. FGFR mutations can cause the FGFR protein to become over-active in diseases
such as cancer. Infigratinib may stop the growth of tumor cells by blocking FGFR proteins in
these tumors.